Approaches to Treatment and Staging in Unresectable NSCLC

January 23, 2024

By Gregory Gan, MD, PhD
Alykhan Nagji, MD

Opinion

Video

Gregory Gan, MD, briefly outlines the available treatment strategies for stage III unresectable NSCLC, and Alykhan Nagji, MD explores the characterization of patients with unresectable stage III NSCLC, underscoring the crucial role of accurate staging in guiding treatment decisions.

EP: 1.Available Treatment Options for Patients With Stage-III Resectable NSCLC

EP: 2.Determining Eligibility for Surgical Resection in NSCLC

EP: 3.Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC

EP: 4.Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting

EP: 5.Treatment Strategies for NSCLC Following Progression on Adjuvant Immunotherapy

Now Viewing

EP: 6.Approaches to Treatment and Staging in Unresectable NSCLC

EP: 7.Sequential and Concurrent Chemoradiotherapy in Unresectable Stage-III NSCLC

EP: 8.Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC

EP: 9.Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations

EP: 10.The Potential Role of Combination Adjuvant Immunotherapy in NSCLC

EP: 11.Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy

EP: 12.Clinical Pearls for Treating NSCLC: Insights from Experts at the University of Kansas

EP: 13.Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%

EP: 14.Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%

EP: 15.Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%

EP: 16.Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment

EP: 17.A Multidisciplinary Approach to Treating Resectable NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!